Status:
ENROLLING_BY_INVITATION
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
Lead Sponsor:
Xenon Pharmaceuticals Inc.
Conditions:
Bipolar Depression
Bipolar I Disorder
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
X-CEED-OLE is a Phase 3, multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner in adult participants who successfully completed an antecendent Phase...
Eligibility Criteria
Inclusion
- Participant successfully completed the treatment period in a Phase 3 antecedent study evaluating azetukalner in participants with bipolar depression.
- Participant provides written informed consent to participate in the study, is able to understand the procedures and study requirements, and agrees to abide by them.
- Participant is willing to comply with the contraception requirements.
Exclusion
- Participant met any of the withdrawal criteria, discontinued study drug early, or was terminated early from an antecedent study.
- Participant had any protocol deviations in an antecedent study that, in the opinion of the investigator, would preclude participation in this study.
- Participant has any medical condition, personal circumstance, or ongoing AE (from an antecedent study) that, in the opinion of the investigator, exposes the participant to unacceptable risk by participating in the study or prevents adherence to the protocol.
- Participant is pregnant, breastfeeding, or planning to become pregnant.
- Participant is planning to enter a clinical study with a different investigational drug or planning to use any experimental device for the treatment of any medical condition during the study or within 28 days after completion of this study.
- Participant is judged by the investigator to have a significant risk for self-harm or suicidal behavior during their participation in the study or is considered to be an imminent danger to themself or others.
Key Trial Info
Start Date :
October 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2029
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT07217860
Start Date
October 30 2025
End Date
August 1 2029
Last Update
December 19 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Woodland International Research Group
Little Rock, Arkansas, United States, 72211
2
Woodland Research Northwest
Rogers, Arkansas, United States, 72758
3
Clinical Neuroscience Solutions
Orlando, Florida, United States, 32801
4
Clinical Neuroscience Solutions Memphis
Memphis, Tennessee, United States, 38119